Study of AMV564 in Patients With AML
Public ClinicalTrials.gov record NCT03144245. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, First in Human, Open Label, Dose Escalation Study of AMV564, a CD33 x CD3 Tandem Diabody in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Study identification
- NCT ID
- NCT03144245
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Amphivena Therapeutics, Inc.
- Industry
- Enrollment
- 53 participants
Conditions and interventions
Conditions
Interventions
- AMV564 Biological
- AMV564 in combination with pembrolizumab Combination Product
Biological · Combination Product
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 19, 2017
- Primary completion
- Jul 20, 2020
- Completion
- Nov 4, 2020
- Last update posted
- Oct 11, 2021
2017 – 2020
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, San Francisco | San Francisco | California | 94143 | — |
| Northwestern | Chicago | Illinois | 60611 | — |
| Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| New York Medical College | Hawthorne | New York | 10532 | — |
| Weill Cornell Medical College, The New York Presbyterian Hospital | New York | New York | 10021 | — |
| The Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| MD Anderson Cancer Center, The University of Texas | Houston | Texas | 70030-4009 | — |
| Fred Hutchinson Cancer Research | Seattle | Washington | 98109-1024 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03144245, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 11, 2021 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03144245 live on ClinicalTrials.gov.